50% of US drug launches in 2023 missed first-year revenue targets

The news: Half of US pharmaceuticals launched in 2023 underperformed their first-year forecasts, while 39% overperformed, according to an analysis from Trinity Life Sciences.

  • Trinity compared the sales performance of new product launches relative to their pre-launch first-year revenue forecasts.

You've read 0 of 2 free articles this month.

Get more articles - create your free account today!